-
FDA Approves Faster Keytruda® Injections for Mesothelioma Patients
28 Oct 2025 15:59 GMT
… Injection Means for Mesothelioma Patients
For patients with mesothelioma, the new … treatment.
Maintains treatment effectiveness: Clinical trials show that the new injection … for multiple rounds: Many mesothelioma patients require repeated treatments. The …
-
AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved >90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026
27 Oct 2025 12:00 GMT
… both epithelial and non-epithelioid mesothelioma models
Quantified anti-tumor activity … to finalize clinical development plans for TT-4 in mesothelioma, with first … but not limited to: regarding clinical trial outcomes and regulatory approvals; uncertainty …
-
AlphaTON Capital and Cyncado Therapeutics Share New Mesothelioma Data Supporting TT-4’s Path to First- Patient Dosing
25 Oct 2025 16:30 GMT
… in-human evaluation. In human mesothelioma spheroid systems, hypoxia-linked … monotherapy activity in an immunocompetent mesothelioma model, and combination treatment … but not limited to: regarding clinical trial outcomes and regulatory approvals; uncertainty …
-
AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth
22 Oct 2025 16:00 GMT
… In an immunocompetent in vivo mesothelioma model, TT-4 monotherapy outperformed … with an initial focus on mesothelioma, advancing toward first-patient dosing … not limited to: uncertainty regarding clinical trial outcomes and regulatory approvals; uncertainty …
-
VT3989 shows promising antitumor activity in refractory mesothelioma patients
22 Oct 2025 12:39 GMT
… trial enrolled 172 patients, including 135 with refractory mesothelioma. Of the 22 mesothelioma … support the continued clinical development of VT3989 in mesothelioma, and we look … this a major unmet clinical need.
Previous trial updates
Initial data from …
-
<![CDATA[Durvalumab/Chemotherapy Prove Inconclusive in Phase 3 for Mesothelioma]]>
19 Oct 2025 19:43 GMT
… to the interpretation of this clinical trial, and of course, chemotherapy alone … president-elect of the International Mesothelioma Interest Group.
REFERENCES:
1. Nowak … in advanced pleural Mesothelioma – A phase 3 Randomised trial. Presented at: 2025 …
-
VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
19 Oct 2025 17:04 GMT
… into Phase 3 Registrational Trial in Mesothelioma Patients in First … Phase 1/2 clinical trial of its first-in- … a registrational Phase 3 trial in mesothelioma in the first … VT3989 into a registrational clinical trial for mesothelioma."
The ongoing …
-
ESMO 2025: VT3989 Demonstrates Promising Early Outcomes in Advanced Mesothelioma Patients
19 Oct 2025 16:41 GMT
… frequently observed in mesothelioma.
The Phase I/II clinical trial enrolled 172 … /II clinical trial studyrefractory mesothelioma researchtargeted therapies for cancerVT3989 clinical trial resultsYAP-TEAD inhibitor …
-
<![CDATA[Imfinzi With Chemo Produces Inconclusive Outcomes in Phase 3 Mesothelioma Study]]>
19 Oct 2025 20:04 GMT
… advanced pleural mesothelioma, echoing findings from earlier phase 2 trials. Despite these … pandemic and by changes in clinical practice following the CheckMate 743 … in advanced pleural Mesothelioma: A phase 3 Randomised trial," by Dr …
-
ESMO 2025: VT3989 Continues to Show Promising Early Results in Patients with Advanced Mesothelioma
19 Oct 2025 18:44 GMT
… a focus on refractory mesothelioma
In this trial, VT3989 demonstrated notable antitumor … support the continued clinical development of VT3989 in mesothelioma, and we look …
About
© 1995-2025